Literature DB >> 23665153

Muscle wasting in heart failure: An overview.

Stephan von Haehling1, Lisa Steinbeck, Wolfram Doehner, Jochen Springer, Stefan D Anker.   

Abstract

Patients with heart failure are frequently limited in their exercise capacity. Although this clinical phenomenon is mostly attributed to the failing myocardium, the effects of skeletal muscle wasting should not be underestimated. Muscle wasting may present in the form of loss of muscle mass and function, termed sarcopenia in healthy aging, or in the form of cachexia. Only cachexia is associated with loss of body weight. The mechanisms involved embrace an anabolic-/catabolic imbalance with increased degradation of myofibrils and myocyte apoptosis. Clinical effects include reduced muscle mass, strength and consequently reduced exercise capacity. This article describes the terminology, molecular pathways, prevalence, clinical implications and possible treatment approaches to muscle wasting in patients with heart failure. This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cachexia; Heart failure; Mechanism; Muscle wasting; Sarcopenia

Mesh:

Year:  2013        PMID: 23665153     DOI: 10.1016/j.biocel.2013.04.025

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  40 in total

1.  Regulating PPARδ signaling as a potential therapeutic strategy for skeletal muscle disorders in heart failure.

Authors:  Ronald B Myers; Jun Yoshioka
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-13       Impact factor: 4.733

2.  [Exercise training as a key component of heart failure therapy].

Authors:  M Dörr; M Halle
Journal:  Herz       Date:  2015-04       Impact factor: 1.443

3.  Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure.

Authors:  Jozine M ter Maaten; Kevin Damman; Hans L Hillege; Stephan J Bakker; Stefan D Anker; Gerjan Navis; Adriaan A Voors
Journal:  Clin Res Cardiol       Date:  2014-07-03       Impact factor: 5.460

Review 4.  Chronic kidney disease and premature ageing.

Authors:  Jeroen P Kooman; Peter Kotanko; Annemie M W J Schols; Paul G Shiels; Peter Stenvinkel
Journal:  Nat Rev Nephrol       Date:  2014-10-07       Impact factor: 28.314

5.  Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure.

Authors:  Masakazu Saitoh; Marcelo Rodrigues Dos Santos; Nicole Ebner; Amir Emami; Masaaki Konishi; Junichi Ishida; Miroslava Valentova; Anja Sandek; Wolfram Doehner; Stefan D Anker; Stephan von Haehling
Journal:  Wien Klin Wochenschr       Date:  2016-11-16       Impact factor: 1.704

Review 6.  Publication trends in cachexia and sarcopenia in elderly heart failure patients.

Authors:  Jochen Springer; Stefan D Anker
Journal:  Wien Klin Wochenschr       Date:  2016-11-24       Impact factor: 1.704

Review 7.  Amino acids and derivatives, a new treatment of chronic heart failure?

Authors:  Valentina Carubelli; Anna Isotta Castrini; Valentina Lazzarini; Mihai Gheorghiade; Marco Metra; Carlo Lombardi
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

Review 8.  Reactive Oxygen Species/Nitric Oxide Mediated Inter-Organ Communication in Skeletal Muscle Wasting Diseases.

Authors:  Lucia M Leitner; Rebecca J Wilson; Zhen Yan; Axel Gödecke
Journal:  Antioxid Redox Signal       Date:  2017-01-04       Impact factor: 8.401

Review 9.  Integration target site selection for retroviruses and transposable elements.

Authors:  X Wu; S M Burgess
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

Review 10.  Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Authors:  Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.